Seoul, Seoul-t'ukpyolsi, South Korea Shinhan Private Equity appeared to be the VC, which was created in 2004. The fund was located in Asia if to be more exact in South Korea. Shinhan Private Equity appeared to be a CVC structure as part of the corporation. The main department of described VC is located in the Seoul.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Shinhan Private Equity, startups are often financed by Symbiosis Group, SunStates Fund, Shumway Capital. The meaningful sponsors for the fund in investment in the same round are QUAD Investment Management, UTC Investment Co., UBS Oncology Impact Fund.
The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2019.
Among the most successful fund investment fields, there are Business Development, Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline CDNetworks, Vedanta Biosciences, Oncorus Besides, a startup needs to be aged 6-10 years to get the investment from the fund.
Related Funds
Funds with similar focus
| Fund Name | Location |
| BCM Technologies (BCMT) | Houston, Texas, United States |
| Blackbirdsport | Beijing, China, Haidian |
| GCM | Japan, Tokyo |
| Genesis Merchant Capital | New York, New York, United States |
| Gray Matters Capital | Atlanta, Georgia, United States |
| Jingzhou Gucheng State-owned Investment Co., Ltd | China, Hubei, Jingzhou |
| Onkyo | Japan, Osaka, Osaka Prefecture |
| Tiny Capital | British Columbia, Canada, Victoria |
| TriplePoint Venture Growth | California, Menlo Park, United States |
| Yongchuang Capital | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Vedanta Biosciences | $16M | 23 Sep 2019 | Cambridge, Massachusetts, United States | ||
Oncorus | $79M | 21 Aug 2019 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Vedanta Biosciences | $16M | 23 Sep 2019 | Cambridge, Massachusetts, United States | ||
Oncorus | $79M | 21 Aug 2019 | Cambridge, Massachusetts, United States |
